全球基因組學和個人化醫療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

基因組學和個人化健康市場預計將從 2025 年的 121.3 億美元成長到 2034 年的 355.1 億美元，2026 年至 2034 年的複合年成長率為 12.67%。

受精準醫療日益普及和基因研究進展的推動，全球基因組學和個人化醫療市場正經歷快速成長。個人化醫療解決方案利用基因組資訊制定個人化的治療方法和預防策略。慢性病盛行率的上升和對標靶治療需求的成長是市場擴張的主要驅動力。此外，定序技術的進步使得基因組分析更加精準且經濟實惠。

關鍵成長要素包括基因組研究投資的增加以及基因檢測在醫療保健領域的日益普及。面向消費者的基因檢測服務的擴展也促進了市場成長。此外，人工智慧 (AI) 和巨量資料分析的融合提高了基因組數據解讀的準確性。人們對預防醫學和疾病早期檢測的日益關注正在推動個人化健康解決方案的普及。

未來，隨著生物技術和數據分析的不斷進步，基於基因組學的個人化醫療市場預計將顯著成長。更精準、更易用的基因組分析工具的開發將進一步加速其應用。在新興市場，由於醫療保健領域的投資不斷增加，預計將迎來強勁的成長機會。此外，持續的研發也將擴大基因組學在醫療保健領域的應用範圍。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球基因體學與個人化醫療市場：依技術分類

• 市場分析、洞察與預測
• NGS平台
• RT-PCR
• 微陣列
• 基因分析裝置
• 其他

第5章 全球基因體學與個人化醫療市場：依檢測類型分類

• 市場分析、洞察與預測
• 腫瘤檢查
• 傳染病檢查
• 罕見疾病檢測
• 自體免疫疾病檢測
• 產科檢查
• 其他

第6章：全球基因體學與個人化醫療市場：依最終用戶分類

• 市場分析、洞察與預測
• 學術機構和研究機構
• 診斷中心
• 其他

第7章 全球基因體學與個人化醫療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • QIAGEN
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories Inc
  • Hoffmann-La Roche AG
  • Lonza Group
  • Invitae Corp
  • Genetic Technologies Limited
  • Interleukin Genetics Inc
  • Eastern Biotech And Life Sciences
  • DNA Genotek Inc
  • UBiome Inc
  • XCode Life Sciences Private Limited

The Genomics Personalized Health Market size is expected to reach USD 35.51 Billion in 2034 from USD 12.13 Billion (2025) growing at a CAGR of 12.67% during 2026-2034.

The global genomics personalized health market is witnessing rapid growth due to increasing adoption of precision medicine and advancements in genetic research. Personalized health solutions use genomic information to tailor treatments and preventive strategies for individuals. The rising prevalence of chronic diseases and the growing demand for targeted therapies are key factors driving market expansion. Additionally, advancements in sequencing technologies are enabling more accurate and affordable genomic analysis.

Key growth drivers include increasing investments in genomics research and the growing use of genetic testing in healthcare. The expansion of direct-to-consumer genetic testing services is also contributing to market growth. Furthermore, the integration of artificial intelligence and big data analytics is enhancing the interpretation of genomic data. The rising focus on preventive healthcare and early disease detection is supporting the adoption of personalized health solutions.

In the future, the genomics personalized health market is expected to grow significantly with continuous advancements in biotechnology and data analytics. The development of more precise and accessible genomic tools will further drive adoption. Emerging markets are likely to offer strong growth opportunities due to increasing healthcare investments. Additionally, ongoing research and innovation will expand the applications of genomics in healthcare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• NGS Platform
• RT-PCR
• Microarray
• Genetic Analyzer
• Others

By Test Type

• Oncology Testing
• Infectious Disease Testing
• Orphan Disease Testing
• Autoimmune Disease Testing
• Obstetrics Testing
• Others

By End-user

• Academics & Research Institutes
• Diagnostic Centers
• Others

COMPANIES PROFILED

• QIAGEN, Illumina Inc, Thermo Fisher Scientific Inc, BioRad Laboratories Inc, HoffmannLa Roche AG, Lonza Group, Invitae Corp, Genetic Technologies Limited, Interleukin Genetics Inc, Eastern Biotech and Life Sciences, DNA Genotek Inc, uBiome Inc, XCode Life Sciences Private Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. NGS Platform Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. RT-PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Microarray Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Genetic Analyzer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Test Type
• 5.2. Oncology Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Infectious Disease Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Orphan Disease Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Autoimmune Disease Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Obstetrics Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Academics & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Test Type
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Test Type
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Test Type
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Test Type
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Test Type
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENOMICS PERSONALIZED HEALTH INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 QIAGEN
  • 9.2.2 Illumina Inc
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Bio-Rad Laboratories Inc
  • 9.2.5 Hoffmann-La Roche AG
  • 9.2.6 Lonza Group
  • 9.2.7 Invitae Corp
  • 9.2.8 Genetic Technologies Limited
  • 9.2.9 Interleukin Genetics Inc
  • 9.2.10 Eastern Biotech And Life Sciences
  • 9.2.11 DNA Genotek Inc
  • 9.2.12 UBiome Inc
  • 9.2.13 XCode Life Sciences Private Limited